Twenty-four-month interim results from a prospective, single-arm clinical trial evaluating the performance and safety of cellular bone allograft in patients undergoing lumbar spinal fusion

Twenty-four-month interim results from a prospective, single-arm clinical trial evaluating the performance and safety of cellular bone allograft in patients undergoing lumbar spinal fusion

Abstract Background Autologous bone grafts are the gold standard for spinal fusion; however, harvesting autologous bone can result in donor site infection, hematomas, increased operative time, and prolonged pain. Cellular bone allografts (CBAs) are a viable alternative that avoids the need for bone...

Full description

Bibliographic Details
Main Authors: Daniel K. Park, Joshua J. Wind, Todd Lansford, Pierce Nunley, Timothy A. Peppers, Anthony Russo, Hamid Hassanzadeh, Jonathan Sembrano, Jung Yoo, Jonathan Sales
Format: Article
Language:English
Published: BMC 2023-11-01
Series:BMC Musculoskeletal Disorders
Subjects:
Lumbar fusion
Arthrodesis
Cellular allograft
Trinity Elite
CBA
Online Access:https://doi.org/10.1186/s12891-023-06996-5

Internet

https://doi.org/10.1186/s12891-023-06996-5

Similar Items